Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
NextGen Therapeutics | Whitepapers & Reports

Biosimilar Structural Comparison of Commercially Sourced Reference Standards by MMS Rapidly Detects Subtle but Critical Differences to Correctly Predict Activity for Use in an ELISA Product

22 March 2022
Open document in a new tab

Related Resources

FDA's AI Model Enhances Safety of Biosimilar Therapeutic Proteins

Thanks to the FDA's new AI-powered imaging tool, the safety profile of newly developed biosimilar therapeutic protiens may improve.
Read More

Biocon’s Biosimilar Difficulties: Successive FDA Rejections Don’t Inspire Hope

Biocon suffer another FDA rejection due to data and manufacturing concerns, this time for their bevacizumab biosimilar.
Read More